Which of the following statements about LABAs is true?

Which of the following statements about LABAs is true?

• A. LABAs can be used as monotherapy.
• B. LABAs are contraindicated in all patients.
• C. LABAs should always be used in combination with ICS.
• D. LABAs have no effect on asthma management.

Answer: (C)

The statement that LABAs (Long-Acting Beta-Agonists) should always be used in combination with ICS (Inhaled Corticosteroids) is correct due to the established guidelines and evidence supporting their combined use for effective asthma management. LABAs are effective bronchodilators that help to open the airways in patients with asthma or COPD, providing relief from symptoms such as wheezing and difficulty breathing. However, when used as monotherapy, LABAs have been associated with an increased risk of adverse outcomes, particularly asthma-related events such as hospitalizations and deaths. The combination of LABAs with ICS is critical because ICS address the underlying inflammation associated with asthma and help to improve overall control of the disease. By combining these two classes of medications, the anti-inflammatory effects of ICS can complement the bronchodilatory effects of LABAs, resulting in better management of asthma symptoms and reduced risk of exacerbations. Thus, the recommendation to use LABAs along with ICS forms the foundation of treatment for moderate to severe persistent asthma, aligning with clinical practice guidelines that emphasize safety and efficacy in asthma management.

The statement that LABAs (Long-Acting Beta-Agonists) should always be used in combination with ICS (Inhaled Corticosteroids) is correct due to the established guidelines and evidence supporting their combined use for effective asthma management. LABAs are effective bronchodilators that help to open the airways in patients with asthma or COPD, providing relief from symptoms such as wheezing and difficulty breathing. However, when used as monotherapy, LABAs have been associated with an increased risk of adverse outcomes, particularly asthma-related events such as hospitalizations and deaths.

The combination of LABAs with ICS is critical because ICS address the underlying inflammation associated with asthma and help to improve overall control of the disease. By combining these two classes of medications, the anti-inflammatory effects of ICS can complement the bronchodilatory effects of LABAs, resulting in better management of asthma symptoms and reduced risk of exacerbations.

Thus, the recommendation to use LABAs along with ICS forms the foundation of treatment for moderate to severe persistent asthma, aligning with clinical practice guidelines that emphasize safety and efficacy in asthma management.